We are live on
!
Find out more
VIA
Vident Investment Advisory Portfolio holdings
AUM
$2.9B
1-Year Est. Return
24.67%
This Fund
S&P 500
This Quarter
Est. Return
+4.29%
1 Year Est. Return
+24.67%
3 Year Est. Return
+82.63%
5 Year Est. Return
+113.33%
10 Year Est. Return
–
AUM
$1.24B
AUM Growth
-$612M
(-33%)
Cap. Flow
-$654M
Cap. Flow
% of AUM
-52.6%
Top 10 Holdings %
Top 10 Hldgs %
19.67%
Holding
716
New
21
Increased
155
Reduced
258
Closed
281
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Omnicell
OMCL
|
+$12.9M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$10.1M |
| 3 |
BEAT
BioTelemetry, Inc.
BEAT
|
+$4.38M |
| 4 |
IRBT
iRobot
IRBT
|
+$4.37M |
| 5 |
3D Systems Corp
DDD
|
+$3.83M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Lincoln Electric
LECO
|
+$12.9M |
| 2 |
Azenta
AZTA
|
+$7.28M |
| 3 |
Oceaneering
OII
|
+$4.55M |
| 4 |
PSB
PS Business Parks, Inc.
PSB
|
+$4.04M |
| 5 |
Prologis
PLD
|
+$3.99M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.58% |
| 2 | Healthcare | 14.8% |
| 3 | Industrials | 9.69% |
| 4 | Consumer Discretionary | 5.64% |
| 5 | Consumer Staples | 2.97% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Fate Therapeutics
FATE
$326M
| $1.68M | 0.14% |
82,719
-13,596
| -14% | -$245K |
|
|
ONC
102
BeOne Medicines Ltd
ONC
$38.7B
| $1.68M | 0.14% |
13,546
-234
| -2% | -$29.7K |
|
103
Kroger
KR
$34.8B
| $1.67M | 0.13% |
76,852
-84,683
| -52% | -$2.06M |
|
104
MarketAxess Holdings
MKTX
$5.72B
| $1.66M | 0.13% |
5,166
-1,283
| -20% | -$371K |
|
105
Evergy
EVRG
$19.2B
| $1.65M | 0.13% |
27,431
+1,656
| +6% | +$96.9K |
|
106
argenx
ARGX
$54.1B
| $1.64M | 0.13% |
11,546
-3,414
| -23% | -$433K |
|
107
Alaunos Therapeutics
TCRT
$4.86M
| $1.62M | 0.13% |
+1,857
| New | +$1.28M |
|
108
MacroGenics
MGNX
$257M
| $1.61M | 0.13% |
94,915
-9,856
| -9% | -$169K |
|
109
NextEra Energy
NEE
$177B
| $1.59M | 0.13% |
31,144
-956
| -3% | -$47K |
|
110
Regeneron Pharmaceuticals
REGN
$80.8B
| $1.59M | 0.13% |
5,088
+655
| +15% | +$218K |
|
111
Cboe Global Markets
CBOE
$29.9B
| $1.58M | 0.13% |
15,262
-115
| -0.7% | -$11.9K |
|
112
Zymeworks
ZYME
$1.73B
| $1.56M | 0.13% |
+71,026
| New | +$1.3M |
|
113
IBM
IBM
$224B
| $1.56M | 0.13% |
11,822
+29
| +0.2% | +$3.81K |
|
114
Clorox
CLX
$12.7B
| $1.55M | 0.12% |
10,139
+114
| +1% | +$17.4K |
|
115
Precision BioSciences
DTIL
$207M
| $1.55M | 0.12% |
+3,898
| New | +$1.57M |
|
116
CRISPR Therapeutics
CRSP
$5.17B
| $1.55M | 0.12% |
+32,833
| New | +$1.31M |
|
117
Sempra
SRE
$54.8B
| $1.55M | 0.12% |
22,492
-1,088
| -5% | -$71.4K |
|
118
Ventas
VTR
$47.9B
| $1.54M | 0.12% |
22,489
-19,070
| -46% | -$1.22M |
|
|
YMAB
119
DELISTED
Y-mAbs Therapeutics
YMAB
| $1.52M | 0.12% |
66,416
-5,450
| -8% | -$125K |
|
120
AstraZeneca
AZN
$250B
| $1.5M | 0.12% |
18,215
-1,950
| -10% | -$153K |
|
|
BLUE
121
DELISTED
bluebird bio
BLUE
| $1.49M | 0.12% |
905
-284
| -24% | -$491K |
|
122
Allogene Therapeutics
ALLO
$694M
| $1.46M | 0.12% |
54,332
-4,998
| -8% | -$139K |
|
|
SGEN
123
DELISTED
Seagen Inc. Common Stock
SGEN
| $1.46M | 0.12% |
21,084
-4,259
| -17% | -$298K |
|
|
AUTL
124
Autolus Therapeutics
AUTL
$562M
| $1.46M | 0.12% |
+90,425
| New | +$2.02M |
|
125
Chevron
CVX
$366B
| $1.45M | 0.12% |
11,624
-20,773
| -64% | -$2.51M |
|
Similar funds
EST
TCM
AWS
WI
JP
VCM
FCB
FCFS
Vident Investment Advisory's Q2 2019 Portfolio in Review
As of Q2 2019, Vident Investment Advisory held 716 positions worth $1.24B, down 33% from $1.85B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Vident Investment Advisory withdrew a net $654M in Q2 2019, closing 281 positions and reducing 258 holdings. Its most notable exit was Lincoln Electric, an estimated $12.9M position sold in full.
By sector, the portfolio is most concentrated in Technology at 29% of assets, up from 23% a quarter earlier, followed by Healthcare and Industrials.
Against the trend, Vident Investment Advisory opened a new position in Omnicell worth $13.7M.
- Vident Investment Advisory's largest Q2 2019 buy was Omnicell: 159,055 shares worth $13.7M.
- Vident Investment Advisory added most to State Street SPDR S&P 500 ETF Trust in Q2 2019, an estimated $10.1M increase.
- Vident Investment Advisory's biggest Q2 2019 reduction was Azenta, cutting an estimated $7.28M.
- Vident Investment Advisory fully exited Lincoln Electric in Q2 2019, selling an estimated $12.9M.
- Vident Investment Advisory's ten largest holdings make up 20% of its $1.24B portfolio in Q2 2019.
- Vident Investment Advisory opened 21 new positions and closed 281 in Q2 2019.
- Vident Investment Advisory's portfolio value fell 33% quarter-over-quarter to $1.24B.
Based on Vident Investment Advisory's 13F filing for Q2 2019, filed 12 Aug 2019.